TSE:4502

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. More Details


Snowflake Analysis

Solid track record second-rate dividend payer.


Similar Companies

Share Price & News

How has Takeda Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4502 is less volatile than 75% of JP stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4502's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

8.1%

4502

0.4%

JP Pharmaceuticals

-0.9%

JP Market


1 Year Return

6.1%

4502

18.7%

JP Pharmaceuticals

36.1%

JP Market

Return vs Industry: 4502 underperformed the JP Pharmaceuticals industry which returned 12.9% over the past year.

Return vs Market: 4502 underperformed the JP Market which returned 28.5% over the past year.


Shareholder returns

4502IndustryMarket
7 Day8.1%0.4%-0.9%
30 Day6.3%-5.2%-0.4%
90 Day1.2%-2.3%7.0%
1 Year11.5%6.1%21.2%18.7%39.5%36.1%
3 Year-22.0%-31.3%25.2%16.6%16.6%8.6%
5 Year-13.3%-28.6%46.5%30.3%53.8%36.8%

Long-Term Price Volatility Vs. Market

How volatile is Takeda Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Takeda Pharmaceutical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 4502 (¥3905) is trading below our estimate of fair value (¥8240.26)

Significantly Below Fair Value: 4502 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 4502 is poor value based on its PE Ratio (33.7x) compared to the JP Pharmaceuticals industry average (22.2x).

PE vs Market: 4502 is poor value based on its PE Ratio (33.7x) compared to the JP market (17.1x).


Price to Earnings Growth Ratio

PEG Ratio: 4502 is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: 4502's PB Ratio (1.3x) is in line with the JP Pharmaceuticals industry average.


Next Steps

Future Growth

How is Takeda Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

19.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4502's forecast earnings growth (19.8% per year) is above the savings rate (0%).

Earnings vs Market: 4502's earnings (19.8% per year) are forecast to grow faster than the JP market (17.4% per year).

High Growth Earnings: 4502's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4502's revenue (0.8% per year) is forecast to grow slower than the JP market (5.7% per year).

High Growth Revenue: 4502's revenue (0.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4502's Return on Equity is forecast to be low in 3 years time (9.9%).


Next Steps

Past Performance

How has Takeda Pharmaceutical performed over the past 5 years?

0.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4502 has high quality earnings.

Growing Profit Margin: 4502's current net profit margins (5.6%) are higher than last year (0.4%).


Past Earnings Growth Analysis

Earnings Trend: 4502 has become profitable over the past 5 years, growing earnings by 0.6% per year.

Accelerating Growth: 4502's earnings growth over the past year (1226.7%) exceeds its 5-year average (0.6% per year).

Earnings vs Industry: 4502 earnings growth over the past year (1226.7%) exceeded the Pharmaceuticals industry 10.9%.


Return on Equity

High ROE: 4502's Return on Equity (3.9%) is considered low.


Next Steps

Financial Health

How is Takeda Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 4502's short term assets (¥2,616.6B) exceed its short term liabilities (¥1,805.0B).

Long Term Liabilities: 4502's short term assets (¥2,616.6B) do not cover its long term liabilities (¥5,841.8B).


Debt to Equity History and Analysis

Debt Level: 4502's debt to equity ratio (101.5%) is considered high.

Reducing Debt: 4502's debt to equity ratio has increased from 31.8% to 101.5% over the past 5 years.

Debt Coverage: 4502's debt is not well covered by operating cash flow (16.9%).

Interest Coverage: 4502's interest payments on its debt are not well covered by EBIT (1.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Takeda Pharmaceutical current dividend yield, its reliability and sustainability?

4.61%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: 4502's dividend (4.61%) is higher than the bottom 25% of dividend payers in the JP market (1.25%).

High Dividend: 4502's dividend (4.61%) is in the top 25% of dividend payers in the JP market (2.88%)


Stability and Growth of Payments

Stable Dividend: 4502's dividends per share have been stable in the past 10 years.

Growing Dividend: 4502's dividend payments have not increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (155.5%), 4502's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.4yrs

Average management tenure


CEO

Christophe Weber (54 yo)

5.92yrs

Tenure

JP¥2,073,000,000

Compensation

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...


CEO Compensation Analysis

Compensation vs Market: Christophe's total compensation ($USD19.15M) is above average for companies of similar size in the JP market ($USD1.89M).

Compensation vs Earnings: Christophe's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Christophe Weber
President5.92yrsJP¥2.07b0.000020%
¥ 1.2m
Constantine Saroukos
CFO & Director1.75yrsJP¥664.00m0%
¥ 0
Masato Iwasaki
President of Japan Pharma Business Unit & Director8.75yrsJP¥297.00m0%
¥ 0
Andrew S. Plump
President of Research & Development and Director5.75yrsJP¥1.05bno data
Seigo Izumo
Chair of Management Boardno datano datano data
Haruhiko Hirate
Member of Management Boardno datano datano data
Salvatore Alesci
Member of Management Board and Head of R&D Global Science & Biomedical Policyno datano datano data
Iwaaki Taniguchi
Senior Vice President of Corporate Finance & Controlling Department8yrsno datano data
Christopher David O'Reilly
Global Head of Investor Relations & Global Finance0.50yrno datano data
Yoshihiro Nakagawa
Global General Counsel6.42yrsno datano data
Mwana Lugogo
Chief Ethics & Compliance Officer6.42yrsno datano data
Ken Araki
Vice President of Global Licensing & Business Development Department9.17yrsno datano data

6.4yrs

Average Tenure

55yo

Average Age

Experienced Management: 4502's management team is seasoned and experienced (6.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christophe Weber
President5.92yrsJP¥2.07b0.000020%
¥ 1.2m
Constantine Saroukos
CFO & Director1.75yrsJP¥664.00m0%
¥ 0
Masato Iwasaki
President of Japan Pharma Business Unit & Director8.75yrsJP¥297.00m0%
¥ 0
Andrew S. Plump
President of Research & Development and Director5.75yrsJP¥1.05bno data
Karen Katen
Member of Takeda Global Advisory Boardno datano datano data
Sidney Taurel
Member of Takeda Global Advisory Boardno datano datano data
Emiko Higashi
Independent External Director4.75yrsJP¥43.00mno data
Bruno Francois Angelici
Member of Takeda Global Advisory Board10.42yrsno datano data
Masahiro Sakane
Independent Chairman of the Board3.75yrsJP¥44.00mno data
Yasuhiko Yamanaka
Director4.75yrsJP¥50.00m0%
¥ 0
Shiro Kuniya
Independent External Director1.75yrsJP¥40.00m0%
¥ 0
Koji Hatsukawa
Independent External Director4.75yrsJP¥42.00m0%
¥ 0

4.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 4502's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Takeda Pharmaceutical Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Takeda Pharmaceutical Company Limited
  • Ticker: 4502
  • Exchange: TSE
  • Founded: 1781
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥5.875t
  • Shares outstanding: 1.56b
  • Website: https://www.takeda.com

Number of Employees


Location

  • Takeda Pharmaceutical Company Limited
  • 1-1, Nihonbashi-Honcho 2-chome
  • Chuo-ku
  • Tokyo
  • 103-8668
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TKPH.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 1992
4502TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYJan 1992
0RN3LSE (London Stock Exchange)YesCommon StockGBEURJan 1992
TKDDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992
TAKNYSE (New York Stock Exchange)SPON ADS EACH REP 0.5 ORD SHSUSUSDMay 2010
TAK NBMV (Bolsa Mexicana de Valores)SPON ADS EACH REP 0.5 ORD SHSMXMXNMay 2010
TKDABST (Boerse-Stuttgart)SPON ADS EACH REP 0.5 ORD SHSDEEURMay 2010
TKDADB (Deutsche Boerse AG)SPON ADS EACH REP 0.5 ORD SHSDEEURMay 2010
TAKP34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REP 1 ADRBRBRLOct 2019

Biography

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other h...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/08 08:13
End of Day Share Price2021/03/08 00:00
Earnings2020/12/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.